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Abstract
Background: Since the first outbreak of a respiratory illness caused by H1N1 virus in Mexico, several reports have
described the need of intensive care or extracorporeal membrane oxygenation (ECMO) assistance in young and
often healthy patients. Here we describe our experience in H1N1-induced ARDS using both ventilation strategy
and ECMO assistance.
Methods: Following Italian Ministry of Health instructions, an Emergency Service was established at the Careggi
Teaching Hospital (Florence, Italy) for the novel pandemic influenza. From Sept 09 to Jan 10, all patients admitted
to our Intensive Care Unit (ICU) of the Emergency Department with ARDS due to H1N1 infection were studied. All
ECMO treatments were veno-venous. H1N1 infection was confirmed by PCR assayed on pharyngeal swab,
subglottic aspiration and bronchoalveolar lavage. Lung pathology was evaluated daily by lung ultrasound (LUS)
examination.
Results: A total of 12 patients were studied: 7 underwent ECMO treatment, and 5 responded to protective
mechanical ventilation. Two patients had co-infection by Legionella Pneumophila. One woman was pregnant. In
our series, PCR from bronchoalveolar lavage had a 100% sensitivity compared to 75% from pharyngeal swab
samples. The routine use of LUS limited the number of chest X-ray examinations and decreased transportation to
radiology for CT-scan, increasing patient safety and avoiding the transitory disconnection from ventilator. No major
complications occurred during ECMO treatments. In three cases, bleeding from vascular access sites due to heparin
infusion required blood transfusions. Overall mortality rate was 8.3%.
Conclusions: In our experience, early ECMO assistance resulted safe and feasible, considering the life threatening
condition, in H1N1-induced ARDS. Lung ultrasound is an effective mean for daily assessment of ARDS patients.
Background
Since the first outbreak of a respiratory illness caused by
Influenza A (H1N1) virus in Mexico [1], several reports
have described the need of intensive care [2-4] or extra-
corporeal membrane oxygenation (ECMO) assistance [5]
in young and often healthy patients.
Beginning August 2009, the Italian Ministry of Health
and the Tuscany Ministry of Health issued instructions
to identify and establish referral centers able to care for
the more severely ill influenza patients. Therefore, sev-
eral referral centers were identified throughout the
national territory among the hospitals already experi-
enced in extracorporeal respiratory support techniques.
The referral ECMO centres, in addition to being capable
of guaranteeing the most advanced treatment in influ-
enza related respiratory failure, were also entrusted with
providing support to the nearby hospitals and assuring
safe transportation.
In the present investigation we report our experience,
as an ECMO referral center, in H1N1-induced acute
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the critical care service planning in response to the
H1N1 pandemic.
Methods
Following the instructions of the Italian Ministry of
Health and Tuscany Regional Ministry of Health, an
Emergency Medical Service was established in the Car-
eggi Hospital in Florence Italy for the novel pandemic
influenza.
The Careggi Hospital ECMO Team is composed of:
an intensivist, a cardiac surgeon, a cardiologist, a nurse,
and a perfusionist. All of the members of the team are
properly trained in ECMO treatment. An ambulance
and a car are equipped with an ECMO circuit, a trans-
port ventilator and all of the materials needed to initiate
extracorporeal support in the peripheral hospitals, and
permit safe transportation while on extracorporeal circu-
lation to our referral hospital.
The requirement of ECMO was decided based on the
Italian Ministry of Health criteria (Table 1).
From September 2009 to January 2010, all patients
admitted to our ICU with severe respiratory failure due
to H1N1 infection were included in this study. Patient
demographics and clinical characteristics were collected
from institutional ICU database (FileMaker Pro, File-
Maker, Inc, USA), from Italian Group for the Evaluation
of Interventions in Intensive Care Medicine database
(GiViTI Margherita Project, Istituto Mario Negri, Ber-
gamo, Italy) and from ECMO national network database.
Discrete variables are expressed as counts and percen-
tages, whereas continuous variables are reported as
medians with 25th to 75th interquartile range (IQR).
The Internal Review Board approved this retrospective
study and informed consent for data publication was
obtained from the patients or relatives.
Ventilation strategy
Pressure volume curves were calculated with ventilator’s
built in application (Draeger Evita XL, Draeger Medical
AG, Lubeck Germany) starting from a PEEP level of
5c mH 2O, with a pressure limit of 40. Ventilation para-
meters were set on the basis of this calculation, with a
PEEP of 2 cmH2O above the lower inflection point of
the pressure-volume curve, and a peek pressure below
the upper inflection point. In all cases, pressure plateau
was limited to 30 cmH2O and the tidal volume was kept
below 6 ml/Kg [6]. Recruitment manoeuvres (40 sec at
40 cmH2O) were performed twice a day, if needed, to
improve pulmonary gas exchange.
ECMO
All ECMO treatments were veno-venous (Maquet Rota-
flow Centrifugal Pumps with Quadrox-D oxygenators,
Maquet, Rastatt, Germany) and biocoated circuits were
used.
Two types of cannulation were used. Initially a venous
withdrawal cannula was inserted via femoral vein
(Edwards Lifesciences Femoral Venous Cannula 22-24
Fr., Edwards Lifescience, Irvine, CA-USA or Maquet
HLS Venous Cannula 21-25 Fr., Maquet Cardiopulmon-
ary AG, Hirrlingen-Germany) and an infusion cannula
in the right jugular vein (Edwards Lifesciences Fem-Flex
II Cannula 20 Fr., Edwards Lifescience, Irvine, CA-USA
or Maquet HLS Arterial Cannula 23 Fr., Maquet Cardio-
pulmonary AG, Hirrlingen-Germany) were adopted.
During the period study Avalon double lumen cannulas
(Avalon Elite Bi-Caval Dual Lumen Catheter 27-31 Fr.,
Avalon Laboratories, Rancho Dominguez, CA - USA)
become available and were inserted through internal
right jugular vein in 2 patients.
Cannulation was conducted percutaneously with Sel-
dinger technique in all cases, and cannulas position was
confirmed by transesophageal echocardiography.
Heparin infusion during extracorporeal lung assistance
was monitored every two hours by bedside aPTT mea-
surement (Hemochron Jr. Signature plus, ITC Europe,
Milan, IT), which was maintained between 50 and 80
seconds. In case of renal replacement therapy require-
ment in ECMO patients, a continuous veno-venous
hemodiafiltration circuit was assembled on the ECMO
circuit (aspiration on pre-pump line, restitution on pre-
oxygenation line).
ECMO patients were ventilated with protective para-
meters, and respiratory rate and ECMO flow were
adjusted to achieve normocarbia and oxygen saturation
above 92%.
Infection control
H1N1 infection was confirmed by real-time reverse
transcriptase-polymerase-chain-reaction (RT-PCR)
Table 1 Italian Ministry of Health criteria to discuss the
need of ECMO
Acute respiratory failure with one of the following condition:
1. SaO2 < 85% for at least 1 hour
2. Oxygenation Index >25 for at least 6 hours after ventilation
optimisation
3. PaO2/FiO2 < 100 with PEEP ≥ 10cmH2O for at least 6 hours after
ventilation’s optimization
4. Hypercapnia with pH < 7.25
5. SvO2 < 65% with hematocrit >30 and under vasoactive drugs
infusion
The parameter are referred to a condition of lung protective ventilation (tidal
volume:4-6 ml/Kg of predicted body weight; plateau pressure ≤ 30 cmH20;
PEEP >lower inflection point of the curve pressure-volume).
PEEP: positive end-expiratory pressure; PaO2: arterial oxygen partial pressure;
FiO2: inspired oxygen fraction; RR: respiratory rate; SaO2: peripheral oxygen
saturation; SvO2: central venous oxygen saturation.
Oxygenation Index: Mean airway pressure (cmH2O) * FiO2 * 100/PaO2;
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bronchoalveolar lavage in accordance with published
guidelines [7]. Bronchoalveolar specimens were obtained
with a mini-invasive system (Kimberly-Clark BAL Cath,
Kimberly-Klark N.V. Zaventem - Belgium), or by
bronchoscopy.
Patients were isolated in negative pressure atmosphere
rooms, and staff wore full protective garments (includ-
ing FFP3 respirators, 3 M Italia SpA, Segrate, Italy),
until 2 consecutive tests werec o n f i r m e dn e g a t i v e .D u r -
ing the study period only one case of suspected trans-
mission of influenza to a nurse occurred.
Antiviral therapy consisted in oral oseltamivir (75 mg
twice daily) and inhaled zanamivir (10 mg twice daily).
Blood and urinary cultures, tracheal aspirate, and
pharyngeal swab were obtained upon patient admission.
Empiric antimicrobial regimen at ICU admission was
initiated with levofloxacin and amoxicillin/clavulanate;
eventually specific antimicrobial therapy was varied or
ended on the basis of microbiological results.
Steroids were administered at low dosage (20 mg
metilprednisolon twice per day) to prevent lung fibrosis.
Diuretics were administered at different dosages,
depending on clinical judgment and the patient’s renal
function.
Lung ultrasound examination
Lung ultra sound (LUS) examinations were daily
performed by the attending physician, with a multi-
frequency convex probe (3.5-5 MHz, Mylab TM 30CV,
ESAOTE, Genova, IT). With the patient in semirecum-
bent position, lateral and anterior views were obtained
from base to apex of the chest. Posterior axillary line
was followed during lateral transversal examinations.
Chest quadrants defined by the intercostal spaces and
the parasternal, mid-clavicular, and anterior axillary
lines were scanned on the anterior chest wall [8]. The
occurrence and extension of parenchymal consolida-
tions, alveolar interstitial syndrome (measured by the
number of B-lines), and morphology of pleural line were
evaluated [9-11]. Pleural effusions were estimated by
using Balik’s formula [12,13]. In order to ensure a uni-
form record, and allow to follow the evolution of the
findings over time, all exams were recorded in an elec-
tronic form, in which the description of the main LUS
features was predetermined [14].
Results
Overall patients
During the study period, 12 patients requiring invasive
ventilation treatment and/or ECMO were admitted or
transferred to our ICU. Baseline and clinical characteris-
tics of patients admitted for H1N1-induced severe
respiratory failure are summarized in Table 2.
The median time between initial, non specific, symp-
toms and respiratory failure was 7 days (IQR 6-8.25),
and severe hypoxia, unresponsiveness to non-invasive
ventilation, was the main clinical feature. Our patients
were young, median age 44.5 years, none of them older
than 58 years, and eight (80%) younger than 50. Two
patients were severely obese (BMI > 40), one woman
was pregnant (18 weeks), two patients had a history of
chronic obstructive respiratory disease (COPD), and one
had diabetes. Two patients had Legionella Pneumophila
coinfection at admission, and one young patient (16
years old) with suspect viral myocarditis and heart
Table 2 baseline and clinical characteristics of H1N1-
pneumonia patients
Number 12
Male sex, N (%) 8 (66 .7%)
Age (years) 44.5 (36.8-48.8)
BMI 27 (23.8-31)
SAPS II 36 (27.75-44.75)
Patients with comorbidities, N (%) 5 (41 .7%)
Patients with proved coinfection, N (%) 2 (16 .7%)
Days from onset to ICU admission 7 (6-8.25)
§ PaO2(mmHg)/FiO2 92 (53.5-119.5)
§ PaCO2 (mmHg) 65 (39.9-83)
§p H 7.37 (7.32-7.50)
§ Respiratory rate (N/min) 8.62 (6.87-11.3)
§ White cells count (N*1000/ml) 8.620 (6.870-11.300)
§ Platelets count (N*1000/ml) 158.5 (102-217.3)
§ Lactate dehydrogenase (U/l) 617 (391.2-919.8)
§ Creatine kinase (U/l) 611 (402.5-893.8)
§ Aspartate aminotransferase (U/l) 53.5 (39.8-121.3)
§ Alanine aminotransferase (U/l) 37.5 (27.3-43.5)
§ C-reactive protein (mg/dl) 80.5 (35.9-132.4)
§ Serum creatinine (mg/dl) 0.87 (0.69-1.26)
§ Procalcitonin (ng/ml) 3.2 (1.1-4.3)
Chest radiographs (mean per patient) 7.3
Chest CT-scan (mean per patient) 1.25
Tracheostomy, N (%) 5 (41 .7%)
ECMO, N (%) 7 (58 .3%)
CVVH, N (%) 2 (16 .7%)
Duration of mechanical ventilation (days) 13.5 (10.8-21.5)
ICU lenght of stay (days) 16.5 (10.5-25.5)
Mortality, N (%) 1 (8 .3%)
Data are referred to first assessment at ICU admission. Continuous data are
represented as medians with 25th to 75th interquartile range (IQR). Percent
data are referred to the total population of each group.
BMI: body mass index; CVVH: continuous veno-venous hemofiltration; ECMO:
extracorporeal membrane oxygenation; SAPS: simplified acute physiology
score.
§ values at ICU admission
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the two coinfected, presented low leukocyte and platelet
count and low plasma procalcitonin levels, significant
levels of lactate dehydrogenase (LDH), creatine kinase
(CK), and C-reactive protein (Table 2). Median duration
of mechanical ventilation (days) was 11.5 (IQR 9.8-16.3)
and median ICU length of stay (days) was 14 (IQR 12-
16.5). The pregnant woman continued the pregnancy
without significant complications.
In ICU infection rate was low with two ventilator
associated pneumonia and two asymptomatic positive
blood cultures in two ECMO patients. One ECMO
patient died due to a systemic secondary infection by
Aspergillus: this patient was the only non-surviving
patient (overall mortality rate 8.3%).
H1N1 infection monitoring and therapy
RT-PCRs from bronchoalveolar lavage samples were
positive in all patients included in this study. On the
contrary, RT-PCR dosed on pharyngeal swab resulted
positive in less than 70% of patients at ICU admission,
and in 90% of patients in the second day (Figure 1).
Also efficacy of antiviral therapy was reliably followed
through RT-PCR from bronchoalveolar samples, since
analysis on pharyngeal swabs became negative quite
early. Finally, no RT-PCR significant for H1N1 infection
from subglottic aspirate sample was found.
In one patient, intravenous administration of zanami-
vir was needed, since the patient remained positive to
viral infection after two weeks of therapy. Intravenous
formulation of zanamivir is still subjected to pre-phase 4
clinical trial investigation, even if some reports on its
safety profile are already available in literature. There-
fore, local Ethical Committee approval was requested
and the manufacturer provided the drug for use. Zana-
mivir was administered intravenously for five days (600
mg twice daily), as indicated by the producer. The
patient’s respiratory function improved and RT-PCR
became negative after the third day. No adverse reaction
was noted.
Lung ultrasound (LUS) examination in H1N1-induced
ARDS
A total of 156 LUS have been performed. During every
LUS, the following parameters were considered: pleural
line aspect and motility, presence of consolidations,
occurrence and severity of Alveolar Interstitial Syn-
drome (based on the number of B-lines), presence of
pleural effusion and occurrence of pneumothorax.
Pleural thickness was described in 100% of cases and
mostly bilaterally. Lung base was always involved. Lung
gliding was present in 70% of LUS, even if decreased
(20%). Pathological Lung Pulse was found in 20%
of LUS, often in proximity to large parenchyma
consolidations. Pleural effusion occurred in 7 patients.
Two spontaneous pneumothorax have been detected
with LUS during ICU treatment.
Alveolar Interstitial Syndrome was present in all ultra-
sound examinations, with the presence of normal lung
pattern (spared areas). In 90% of cases, B-Lines were
described as moderate/many. At lung recovery, residual
B-Lines patterns were found mostly at both bases.
White lung feature occurred in about 15% of LUS per-
formed, mostly in the anterior and lateral scans. White
lung was never uniformly distributed, but it was alter-
nated to spared areas, or areas with a limited number of
B-Lines.
Consolidations were found in 100% of cases. Most of
them were multiple (65%), and lung bases were always
involved. Contiguous subpleural consolidations were
also present, increasing the pleural thickness laterally,
mostly at the base and the apical part. Aerial broncho-
grams were always found within the consolidation
pattern.
The routine use of LUS limited the number of con-
ventional radiology examinations (Table 3). In ECMO
patients group, the higher number of chest X-ray exami-
nations was needed to verify the correct cannulae posi-
tioning. In both groups, bedside LUS limited the
transportation to the CT-scan room, increasing patient
safety and avoiding the transitory disconnection of the
patient from the ventilator.
ECMO patients
ECMO was needed in 7 patients (Table 3). In 4 cases,
the ECMO Team was alerted and extracorporeal oxyge-
nation was implanted directly at peripheral ICUs. No
major transportation related problems were faced, even
in the case of a long distance journey (400 Km). Median
duration of ECMO support was 8 days (IQR 6-16.5),
with a median duration of mechanical ventilation (days)
of 19 (IQR 12-36).
Main clinical features and ventilatory and ECMO
parameters of patients treated with ECMO are presented
in Table 4. Bleeding was the most important complica-
tion. In three cases, bleeding from vascular access sites
due to heparin infusion required blood transfusions.
Three patients presented prolonged oropharyngeal
bleeding and transfusions were required. Among them,
one needed electrical coagulation of a palatine injury,
probably related to nursing manoeuvres. Two patients
presented severe intra-bronchial bleeding, and several
flexible bronchoscopy examinations and clot suctions
were required. In one of these patients, bleeding from
the lower airways during the weaning phase from
ECMO, and ECMO removal has been hastened.
Table 3 summarizes the main differences between
patients who underwent to ECMO treatment and
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ECMO patients clearly showed a higher critical illness
score (SAPS II), and worst pulmonary gas exchange
compared to patients who did not required extracorpor-
eal lung assistance. Coinfection and comorbidities at
admission were present only in ECMO patients.
Discussion
Our study population is young, comprising mainly
healthy subjects, as previously reported [1,2,15]. Risk
factors are similar to other studies, such as obesity, dia-
betes and pregnancy.
In the present case series, bacterial infection rate at
presentation was low. Previous reports showed incidence
of secondary superinfection by Streptococcus Pneumo-
niae, Staphylococcus Aureus, Pseudomonas Aeruginosa,
Acinetobacter Baumannii, Escherichia coli [1,3,2]. In our
experience, we found two cases (16.7%) of co-infection
with Legionella Pneumophila, which is, to the best of
our knowledge, a new epidemiological data, since no
other case has been reported in literature. It is question-
able whether Legionella Pneumophila infection occurred
before or after H1N1 pneumonia. However, it could be
that H1N1 pneumonia was associated with a lower reac-
tivity of the immune system, as suggested by the low
leucocytes count reported in our sample and by other
Authors [3,2,1].
One young patient presented heart failure, and viral
myocarditis was suspected. The association of influenza
with myocarditis is debated [16], and H1N1 related
myocarditis, has rarely been reported [17]. Furthermore,
in our patient prolonged pre-hospital hypoxia was pre-
sent and myocardial hypoxemia damage might have
been involved. The patient required inotrope/vasoactive
support for several days and eventually recovered fully
with normal heart function.
Our observations confirm the responsiveness of this
infection to antiviral therapy. We adopted a two-modality
administration, both oral and inhaled. Our choice was
made in consideration of the decrease in gut motility and
adsorption usually observed in critically ill patients.
The World Health Organization (WHO) has ques-
tioned the sensibility of RT-PCR analysis for H1N1 in
pharyngeal swab sample, encouraging analysis on sam-
p l e sf r o mt h el o w e rr e s p i r a t o r yt r a c t .W er o u t i n e l y
monitor H1N1 infection on three compartments: phar-
yngeal swab, subglottic aspiration, and bronchoalveolar
lavage. In our experience, bronchoalveolar lavage at
admission was positive in all patients while pharyngeal
swab resulted positive in only 75% of cases.
As shown in Figure 1, RT-PCR from pharyngeal swab
at ICU admission failed to demonstrate the viral infec-
tion in 3 patients. Similarly, the time course showed
that RT-PCR from pharyngeal swab resulted negative in
an average time of 3 days after therapy start. Conversely
RT-PCRs from bronchoalveolar lavage remained positive
for a longer period and resulted more reliable for infec-
tion monitoring and assessment of the efficacy of admi-
nistered therapy.
Based on our experience, RT-PCR from bronchoalveo-
lar lavage resulted to be the most reliable method to
diagnose and monitor H1N1 infection, since pharyngeal
swab does not offer enough sensibility, neither for anti-
viral therapy initiation nor for antiviral therapy manage-
ment. As subglottic aspiration resulted persistently
negative, we do not recommend this sampling for diag-
nosis and monitoring of H1N1 infection.
Despite the severe clinical pictures, we experienced a
very low mortality rate: only one patient out of 12 died
(8,3%). One of the surviving patients presented a lung
cavern for a past pulmonary infection, and deceased for
a secondary superinfection by Aspergillus, probably
already colonizing lung parenchyma before the onset of
viral infection.
Our mortality rate is surprisingly low in comparison
to a larger series of H1N1 patients, even when extracor-
poreal support technique were employed [5,18]. Our
finding can be related to the small number of patients
included the study and definitive comparison with larger
studies could be misleading. However, despite the sever-
ity of symptoms and the rapid progression to ARDS,
H1N1 respiratory failure presents a relatively benign
course when adequately treated, if compared to non-
H1N1 induced ARDS, reported to have a mortality rate
from 37% to 43% [19-22]. Several factors may account
for the favourable outcome in our series. All patients
received protective ventilation. In particular, ECMO
support permitted the maintenance of patients under a
protective tidal volume with a respiratory rate below 12
Figure 1 Time course of RT-PCR results on pharyngeal swab
and bronchoalveolar lavage.
Cianchi et al. BMC Pulmonary Medicine 2011, 11:2
http://www.biomedcentral.com/1471-2466/11/2
Page 5 of 9per min, and a FiO2 below 60%, compared with non-
ECMO patients who needed a higher respiratory rate
and FiO2 to maintain an acceptable pulmonary gas
exchange.
The availability of easily accessible tools for pulmonary
mechanics evaluations on modern ventilators allowed an
individualized and appropriate setting of ventilation
pressure within the thresholds of so called “protective
ventilation” [23]. Furthermore, early access to ECMO
resource allowed the maintenance of protective ventila-
tion even in more severe patients (Table 4). In this
regard, lactate dehydrogenase is commonly considered a
marker of lung damage, and in H1N1 pneumonia is
reported as high [1]. In our ECMO patients, lactate
dehydrogenase values presented lower levels than in
non-ECMO patients (445 U/L vs 627 IU/L, respectively),
suggesting that in ECMO patients the reduced need of
pulmonary ventilation could reduce lung ventilatory
stress and enhance healing, regardless of the more
impaired lung condition.
However, it is possible that, since the technique has
gained popularity and experience gathered to demon-
strate its feasibility, we used ECMO also in patients who
m i g h tp r e v i o u s l yh a v eb e e ns u c c e s s f u l l yt r e a t e dc o n v e n -
tionally, and this may have influenced mortality.
Moreover, more than half of our ECMO patients
needed to be land-transported from other hospitals in
an advanced stage of respiratory failure. This may have
Table 3 differences between ECMO and ventilated patients
ECMO patients Non-ECMO patients
Number (%) 75
Male sex, N (%) 6 (85 .7%) 2 (40%)
Age (years) 45 (37-46.5) 42 (39-51)
BMI 27 (23.5-36.5) 27 (25-29)
SAPS II 44 (39-50.5) 28 (27-28)
Patients with comorbidities, N (%) 5 (71 .4%) 2 (40%)
Patients with proved coinfection, N (%) 2 (28 .6%) 0
Days from onset to ICU admission 6 (6-7.5) 7 (7-9)
§ PaO2(mmHg)/FiO2 48.7 (46.8-58) 116 (107-141)
§ PaCO2 (mmHg) 81.6 (60.6-88) 57 (55.8-63)
§p H 7.25 (7.20-7.30) 7.33 (7.28-7.34)
§ Respiratory rate (N/min) 10 (8.5-15) 20 (18-22)
§ PEEP (cmH2O) 14 (11-15) 14 (11-15)
§ Static compliance(ml/cmH2O) 34 (30-38) 32 (23-38)
§ White cells count (N*1000/ml) 11 (9.1-13.3) 7.03 (6.7-8.6)
§ Platelets count (N*1000/ml) 151 (115.5-218.5) 158.5 (125.3-182.5)
§ Lactate dehydrogenase (U/l) 445 (372.5-920.5) 627 (607-632)
§ Creatine kinase (U/l) 477 (189-890.3) 435 (281.5-695)
§ Aspartate aminotransferase (U/l) 54 (42-121.5) 53 (42-78)
§ Alanine aminotransferase (U/l) 38 (25.5-41) 37 (29-45)
§ C-reactive protein (mg/dl) 83.5 (77.5-315.7) 127.5 (96.3-158.8)
§ Serum creatinine (mg/dl) 1.02 (0.79-1.72) 0.81 (0.55-0.85)
§ Procalcitonin (ng/ml) 4.3 (2.7-29.4) 1.9 (0.2-2.6)
CVVH, N (%) 2 (28 .6%) 0
Chest radiographs (mean per patient) 9.6 4.2
Chest CT-scan (mean per patient) 1.6 0.8
Duration of mechanical ventilation (days) 19 (12-36) 9 (5-11)
ICU lenght of stay (days) 23 (17.5-38) 11 (8-14)
Packed Red Blood Cells Units, N 4 (1-6) 1 (0-3)
Mortality, N (%) 1 (14.3%) 0 (0%)
Data on airway pressures and respiratory rate are referred after intubation and recruitment. Continuous data are represented as medians with 25th to 75th
interquartile range (IQR). Percent data are referred to the total population of each group.
BMI: body mass index; CVVH: continuous veno-venous hemofiltration; ECMO: extracorporeal membrane oxygenation; SAPS: simplified acute physiology score.
§ Values at ICU admission
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ensure the safest transport.
Bleeding is commonly reported during ECMO treat-
ment [24], and either anticoagulation or platelet and
coagulation cascade activation through oxygenator and
pump is involved [25].
In our population bleeding also occurred more fre-
quently in ECMO patients, and they required more
transfusions compared to non ECMO patients. Never-
theless, in our experience, bleeding from cannulas inser-
tion site or from upper airways, despite requiring
transfusion, were not life threatening, and could be
managed. In only two cases did severe bleeding occur in
the lower respiratory tract. Fortunately in one case it
occurred during weaning from ECMO, and it ceased
after extracorporeal support removal. The other patient
died from pulmonary aspergillosis and the haemorrhage
could be also related to parenchyma disruption caused
by the fungus.
Monitoring heparin regimen is extremely important
during extracorporeal circulation, and activated clotted
time is commonly measured bedside. Some debate exists
regarding the optimal range and the accuracy of point-
of-care measuring devices [26-28]. In our protocol, we
usually measured aPTT every two hours with Hemo-
chron Jr. in order to closely monitor heparin administra-
tion in the low range of dosage.
In our clinical practice, lung recovery and response
to treatment are daily assessed by LUS examination,
following several recent reports which underline the
reliability of LUS in the evaluation and management of
chest disorders [10,29]. Despite CT-scan is the refer-
ence technique for evaluating lung lesions, it requires a
transitory disconnection of the patient from the venti-
lator to permit the transportation radiology suite with
potential risk of alveolar de-recruitment and worsening
of oxygenation. Moreover, severe complications have
been reported in intra-hospital transportation of criti-
cally ill patients [30,31]. As we recently reported [13],
the routine use of bedside LUS has significantly reduce
of the number of CT-scan and chest X-ray examina-
tions in critical patients. The potential clinical benefit
of reducing in-hospital transport for diagnostic radiol-
ogy, it can be particularly relevant in patients with
ECMO. In these patients, in fact, transportation
requires time and a significant commitment of
resources, although it was proved feasible both for in-
hospital [32,33] and for inter-hospital long distance
transportations [34,35].
Another advantage of LUS is the ability to evaluate the
effectiveness of alveolar recruitment manoeuvres with
the possibility to visualize real-time imagines of lung
parenchyma re-aeration [8,10,29]. Finally, pleural effu-
sions can be accurately diagnosed and monitored with
LUS and in case of need for treatment an ultra-sound
guided technique is recommended [36,13]. This option
seems to be particularly appropriate ECMO patients,
where bleeding for conventional chest tube placement
can occur in consideration of the need of heparin
infusion.
Table 4 main ventilation and ECMO data of patients treated with ECMO
Pre-ECMO parameters In-ECMO parameters (Day 1)
Patient Age
(years)
Comorbidity Peak
Pressure
PEEP tV RR PaO2*C O 2 pH Ventilation
days before
ECMO
Peak
Pressure
PEEP tV RR Pump
Flow
Days
on
ECMO
Ventilation
days after
ECMO
1 15 Asthma 30 14 350 14 50 52 7.18 1 18 10 300 10 5.2 6 3
2 58 - 30 14 400 16 66 76 7.14 2 22 14 300 7 5.0 6 5
3
§ 44 Obesity 33 15 240 20 60 89 7.27 2 28 15 200 9 6.1 15^ 12
4
§ 48 Cigarette
smoke
40 10 700 18 58 54 7.29 1 24 14 270 7 5.9 8 10^
5
§ 30 Asthma,
obesity,
cigarette
smoke
35 15 700 22 48 55 7,22 2 24 14 400 6 5.3 6 3
6
§ 45 Psychiatric
disorder,
emphysema
bulla
45 18 250 20 54 73 7.22 6 28 17 160 8 5.7 37
#^-
7 45 - 35 15 410 32 73 84 7.17 7 25 15 300 20 5.0 18 21^
PEEP: positive end expiratory pressure; RR: respiratory rate; tV: tidal volume.
* Measured with FiO2 = 1
§ Patient referred from another hospital
# Dead on ECMO
^ patient tracheostomized during ECMO
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The present case series comprises a small number of
patients, and naturally, it cannot be considered a high
grade of evidence trial. However, our experience might
be helpful for intensivists challenging H1N1-induced
ARDS. For H1N1 infection monitoring (or diagnosis, if
patient was intubated before) bronchoalveolar lavage
c a nb em o r er e l i a b l et h a np h a r y n g e a ls w a bi no r d e ro f
the higher sensitivity. In our clinical practice, ECMO
therapy resulted safe and feasible in the context of a life
threatening condition, and it might be taken into con-
sideration as a therapeutic choice rather than a rescue
solution in experienced centers.
Key messages
￿ ECMO might be taken into consideration as a safe
therapeutic choice rather than a rescue solution in ARDS.
￿ RT-PCR from bronchial lavage is more accurate than
from pharyngeal swab, in H1N1 diagnosis.
￿ Lung ultrasonography is a safe and reliable method
to follow the pathology evolution/recovery of lung.
￿ Lung ultrasonography can limit the need of CT-scan
and chest X-ray examinations.
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